News Release

Insilico to present the latest advances in chemistry AI at ACS Spring 2021

Meeting Announcement

InSilico Medicine

ACS Spring 2021

image: Insilico to present at the ACS Spring 2021 view more 

Credit: Insilico

April 6, 2021 - Insilico Medicine, a global leader in deep learning for drug discovery and development, will present its latest results in modern and next-generation AI for generative chemistry at the Live ACS Spring 2021 on April 13, 2021.

The presentation will introduce Chemistry42 to the audience and show how it facilitates the discovery of novel small molecule leads in several therapeutic areas. Chemistry42 is a software platform for de novo small molecule design that integrates AI techniques with computational and medicinal chemistry methods. Chemistry42 is unique in its ability to generate novel molecular structures with predefined physicochemical characteristics.

"The role of AI in Chemistry and Drug Discovery has never been more significant than it is today, and it is an honor to contribute to this discussion at the ACS Spring 2021 Conference - a prestigious event that brings together some of the most preeminent scientific minds around the world to connect and share ideas," said Petrina Kamya, PhD., Director of Chemistry42.

"The ACS conference is the Olympics of chemistry and we are happy to present Insilico's Chemistry42 platform at ACS 2021", said Alex Zhavoronkov, CEO, Insilico Medicine. ACS Spring 2021 is an opportunity to participate in 4,000 hours of live interactive technical sessions, poster presentations, and more. Live technical sessions will be held between April 5 - 16. Additional networking events and on-demand technical sessions will be available on April 17 - 30.


For further information, images or interviews, please contact:

About Insilico Medicine

Since 2014 Insilico Medicine has focused on the development of generative models, reinforcement learning (RL), and other modern machine learning techniques for the generation of new molecular structures with the specified parameters, generation of synthetic biological data, target identification, and prediction of clinical trials outcomes. In 2019, Insilico Medicine secured $37 million in series B funding. Since its inception, Insilico Medicine raised over $52 million, published over 100 peer-reviewed papers, applied for over 25 patents, and received multiple industry awards. Website

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.